Researchers have discovered that a metabolic enzyme called AKR1B1 drives an aggressive type of breast cancer. The study, ‘AKR1B1 promotes basal-like breast cancer progression by a positive feedback loop that activates the EMT program,’ suggests that an inhibitor of this enzyme currently used to treat diabetes patients could be an effective therapy for this frequently deadly form of cancer.